 JERSEY, Channel Islands, April 05, 2021 GLOBE NEWSWIRE -- Quotient Limited NASDAQ:QTNT, a commercial-stage diagnostics company the Company, today reported encouraging result from a study of its MosaiQ Multiplex Molecular Disease Screening MDS Microarray, and provided an update regarding progress on the Companys MosaiQTM Expanded Immunohematology IH microarray. 